Skip to main content

Table 3 Cholangiocarcinoma: prior therapy , concurrent chemotherapy, and treatment duration

From: HER2/neu-directed therapy for biliary tract cancer

Pt #

Sites of disease

Prior therapy

HER2/neu test

HER2/neu therapy

Concurrent therapy

Duration of therapy

Overall survival

Best response

1

Liver, mediastinum, Lung

Gemcitabine folfirinox

Mutation (NGS) V777L

Trastuzumab

Gemcitabine, docetaxel

19

29

PD

2

Liver, peritoneum, lung

Gemcitabine + cisplatin

ERBB2 amp NGS

Trastuzumab

FOLFOX

14

25

PD

3

Mediastinum

Gemcitabine + cisplatin, FOLFIRI, GTX

ERBB2 NGS S310F

Trastuzumab

FOLFOX

7

7

PD

4

Liver, lung

Nil

AMPLIFIED (FISH)

Trastuzumab

 

6

8

PD

5

Lung, liver, bones

Gemcitabine + cisplatin

AMPLIFIED (FISH)

Trastuzumab

 

10

12

PD

  1. HER2-positive tumors (IHC 3+, FISH HER2/centromere 17 ratio ≥2.0 or both
  2. SD stable disease, PD progressive disease, CR complete response, PR partial response